BillionaireNet
family
Wilhelm Beier & family
Rank #1348
GERMANYHealthcarePharmaceuticals

Wilhelm Beier & family

Net Worth
$2.96B
-0.08% (24h)
Wilhelm Beier, born on April 21, 1956, is a prominent figure in the pharmaceutical industry. As the founder of Dermapharm, a leading German pharmaceutical company, Beier has built a successful career focused on the manufacture and marketing of patent-free pharmaceuticals. His leadership has been instrumental in Dermapharm's growth, including its role in producing the COVID-19 vaccine Comirnaty. Beier's net worth is estimated at $3 billion, reflecting his significant achievements and strategic acumen in the healthcare sector.

The Full Dossier

Early Life

Wilhelm Beier was born in Eicherscheid (Bad Münstereifel), Germany, on April 21, 1956. Details about his early life and education are limited in the search results, but it is known that he began his career in the pharmaceutical industry in 1981.

Rise to Success

Beier founded Dermapharm in 1991, which specializes in producing patent-free pharmaceuticals. Under his leadership, Dermapharm has grown significantly. A major milestone was reached in October 2020 when the company began producing the COVID-19 vaccine Comirnaty on behalf of BioNTech.

Key Business Strategies

Dermapharm's success is attributed to its integrated business model, which includes in-house product development and manufacturing. The company has expanded its portfolio through strategic acquisitions and internationalization, including a significant presence in Germany. In addition, the company went public in 2018. Beier and his family still own a large portion of the company.

Philanthropy

Information about Wilhelm Beier's specific philanthropic activities and amounts could not be found with the search queries. However, it is known he is involved in youth education and skills development programs.

Career Timeline

2025

Increased Stake in Dermapharm

Further expanded his stake in Dermapharm.

2020

Began production of COVID-19 vaccine

Dermapharm started producing the COVID-19 vaccine Comirnaty on behalf of BioNTech.

2017

Appointed Chairman of the Supervisory Board

Transitioned from CEO to Chairman of the Supervisory Board of Dermapharm.

1991

Founded Dermapharm

Established Dermapharm, a German pharmaceutical company specializing in patent-free pharmaceuticals.

1981

Began career in the pharmaceutical industry

Held various positions, including managing director of German subsidiaries of an international pharmaceuticals manufacturer.

Philanthropic Impact

EducationUndisclosed

Youth Education and Skills Development

Investing in programs focused on empowering South Africa's youth and removing the obstacles they face when seeking employment.

Wealth Trajectory